FierceBiotech Mar 2, 2026 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech Mar 2, 2026 BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
FierceBiotech Mar 2, 2026 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech Mar 2, 2026 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech Mar 2, 2026 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
FierceBiotech Mar 2, 2026 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech Feb 28, 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech Feb 27, 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech Feb 27, 2026 Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
FierceBiotech Feb 27, 2026 FDA slams ExThera with warning letter over controversial blood filter device
FierceBiotech Feb 27, 2026 As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
FierceBiotech Feb 27, 2026 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process